In London, LabGenius Therapeutics, a drug discovery company utilizing machine learning and high-throughput experimentation for therapeutic antibody optimization, has revealed a multi-year research collaboration deal with LG Chem. The agreement involves an option and licensing arrangement with a focus on developing advanced multispecific antibodies to address current limitations of immunotherapies. The goal is to tackle issues like on-target, off-tumour toxicities, and enhance the effectiveness of treatments.